

Studies Open for recruitment at Johns Hopkins Singapore

Liver Cancer

Main Criteria	Study title	Specification	Principle Investigator	Study information website	SC, contact
Any HCC	National Registry of Hepatocellular Carcinoma		Prof. Alex Chang	Not applicale.	Xiaoying, 96446688
1st Line	A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma	CHILD-PUGH 5 & 6.	Dr. Akhil Chopra	http://www.clinicaltrials.gov/ct2/show/NCT01761266?term=Lenvatinib+Versus+Sorafenib&rank=1	Xiaoying, 96446688
2nd line	Protocol XL184-309: A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects with Hepatocellular Carcinoma Who Have Received Prior Sorafenib	CHILD-PUGH A, after sorafenib failed, must has histological or cytological diagnosis of HCC	Dr. Akhil Chopra	http://www.clinicaltrials.gov/ct2/show/NCT01908428?term=Cabozantinib+%28XL184%29&rank=7	Su Mon, 81257417
any line	A Phase I Dose Escalation Study to Investigate the Safety, Immunoregulatory Activity, Pharmacokinetics, and Preliminary Antitumor Activity of Anti-Programmed-Death-1 (PD-1) Antibody (BMS-936558) in Advanced Hepatocellular Carcinoma in Subjects with or without Chronic Viral Hepatitis	Fail or not afford Sorafenib treatment. CHILD-PUGH up to 7. Trial open for Hep B and Hep C by cohort.	Dr. Akhil Chopra	http://www.clinicaltrials.gov/ct2/show/NCT01658878?term=Anti-Programmed-Death-1+%28PD-1%29+Antibody&rank=1	Xiaoying, 96446688

Breast Cancer

Main Criteria	Study title	Specification			SC, contact
Triple negative	Research Data base for women with Triple negative Breast cancer	one time blood draw and obtain tumor tissue	Dr. Lavina Bharwani	Not applicale.	Su Mon, 81257417
1st line or 2nd line metastatic diseases	The study to compare the the safety and efficacy of Lapatinib plus Trastuzumab plus an aromatase Inhibitor (AI) versus trastuzumab plus an AI versus lapatinib plus an AI as first- or second-line therapy in postmenopausal subjects with hormone receptor positive, HER2-positive MBC who have received trastuzumab and endocrine therapies	Triple positive, open.	Dr. Lavina Bharwani	http://www.clinicaltrials.gov/ct2/show/NCT01160211?term=lapatinib+plus&rank=10	Elaine, 90887254
Neoadjuvant	NeoPHOEBE: "Pi3k inhibition in Her2 OverExpressing Breast cancer: A phase II, randomized, parallel cohort, two stage, double-blind, placebo-controlled study of neoadjuvant trastuzumab versus trastuzumab + BKM120 in combination with weekly paclitaxel in HER2-positive, PIK3CA wild-type and PIK3CA mutant primary breast cancer"	Unilateral, >2cm (non-inflammatory), HER2+	Dr. Lavina Bharwani	http://www.clinicaltrials.gov/ct2/show/NCT01816594?term=NeoPHOEBE&rank=1	Poh Yee, 86989500
3rd line or more	A Study of Neratinib plus Capecitabine versus Lapatinib plus Capecitabine in patients with HER2+ metastatic breast cancer who have received two or more prior HER2-directed regimens in the metastatic setting	Her 2 positive. Must have failed 2 lines of HER 2 directed regimens.	Dr. Lavina Bharwani	http://www.clinicaltrials.gov/ct2/show/NCT01808573?term=lapatinib+plus&rank=5	Elaine, 90887254

updated on 14-May-2014